Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 371-378

  Lin, Yvonne S ^a   Nguyen, Cindy ^a   Mendoza, Jose Luis ^a   Escandon, Enrique ^a   Fei, David ^a   Meng, Y Gloria ^a   Modi, Nishit B ^a,b  

^a GENENTECH INC   (United States)

^b ALZA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; RECOMBINANT MONOCLONAL ANTIBODY VEGF; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SOLID TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ENDOTHELIAL GROWTH FACTORS; IODINE RADIOISOTOPES; LYMPHOKINES; MACACA FASCICULARIS; MALE; MICE; MICE, NUDE; RABBITS; RADIOACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032962265     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, D'Amore PA and Miller JW (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 114:66-71.
2. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N and King GL (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487.
3. Arizono H, Ishii S, Nagao T, Kudo S, Sasaki S, Kondo S and Kiyoki M (1994) Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First communication: Plasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits. Arzneim-forsch 44:890-898.
4. Asano M, Yukita A, Matsumoto T, Konda S and Suzuki H (1995) Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor 121. Cancer Res 55:5296-5301.
5. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744.
6. Baxter LT, Zhu H, Mackensen DG, Butler WF and Jain RK (1995) Biodistribution of monoclonal antibodies: Scale-up from mouse to humans using a physiological based pharmacokinetic model. Cancer Res 15:4611-4622.
7. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokin Biopharm 10001-227.
8. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ (1995) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 26:86-91.
9. Chappell WR and Mordenti J (1991) Extrapolation of lexicological and pharmacological data from animals to humans. Adv Drug Res 20:1-116.
10. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M and Rhodes GR (1995) Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Disp 23:1028-1036.
11. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
12. Fava RA, Olsen NJ, Spencer-Green G, Yen KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF and Brown LF (1994) Vascular permeability factor/ endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341-346.
13. Ferrara N (1995) The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36:127-137.
14. Ferrari G and Scagliotti GV (1996) Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients. Eur J Cancer 32A:2368-2369.
15. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
16. Folkman J (1995) Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763.
17. Fox JA, Hotaling TE, Struble C, Ruppel J, Bates DJ and Schoenhoff MB (1996) Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279: 1000-1008.
18. Froehlich J, Schoenhoff M, Tremblay T, Ruppel J and Jardieu P (1995) Initial human study with a humanized recombinant anti-IgE monoclonal antibody: Safety, tolerance and pharmacokinetic (PK)/dynamic profile. Clin Pharmacol Ther 57:162.
19. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki H and Tominaga T (1997) Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 89:139-147.
20. Gibaldi M and Perrier G (1982) Pharmacokinetics, 2nd ed., Marcel Dekker, New York.
21. Gordon MS, Talpaz M, Margolin K, Holmgren E, Sledge GW, Benjamin R, Stalter S, Shak S and Adelman D (1998) Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF Mab) in patients (pts) with metastatic cancer (Abstract). Proc Am Soc Clin Oncol 17:210a.
22. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, Mondini LJ, Tsein W-H, Levin JL, Gallati VH, Korn L, Waldmann TA, Queen C and Benjamin WR (1991) Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 147:1352-1359.
23. Jakeman LB, Winer J, Bennett GL, Altar CA and Ferrara N (1992) Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 89:244-253.
24. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Phillips HS and Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (London) 362:841-844.
25. Lave T, Levet-Trafit B, Schmitt-Hoffmann AH, Morgenroth B, Richter W and Chou RC (1995) Interspecies scaling of interferon disposition and comparison of allometric scaling with concentration-time transformations. J Pharm Sci 84:1285-1290.
26. Matsuzawa K, Koyama T, Sugawara S, Ikegawa S, Asano S, Sasaki S, Tomiyama T, Kasahara Y, Okamiya Y, Inoue K, Ohta T and Makita T (1992) The preclinical safety evaluation of human monoclonal antibody against cytomegalovirus. Fundam Appl Toxicol 19:26-32.
27. Mordenti J (1986) Man versus beast: Pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1039.
28. Mordenti J, Chen SA, Moore JA, Ferraiolo BL and Green JD (1991) Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8:1351-1359.
29. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC and Beierwaltes WH (1983) The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: Evaluation by scintigraphy. J Nucl Med 24:672-682.
30. Presta LG, Chen H, O'Connor SJ, Chisolm V, Meng YG, Krummen L, Winkler M and Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599.
31. Salven P, Mäenpää H, Orpana A, Alitalo K and Joensuu H (1997) Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 3:647-651.
32. Schlaeppi JM, Eppenberger U, Martiny-Baron G and Küng W (1996) Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor-tissue homogenates. Clin Chem 42:1777-1784.
33. Takano S, Yoshii Y, Kondo S, Suzuki H, Maruno T, Shirai S and Nose T (1996) Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 56:2185-2190.
34. Warren RS, Yuan H, Matli MR, Gillett NA and Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797.
35. Yamamoto Y, Toi M, Konda S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T and Tominaga T (1996) Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821-326.